JAGX
Price
$0.32
Change
-$0.07 (-17.95%)
Updated
Dec 5, 6:59 PM EST
QURE
Price
$6.73
Change
-$0.37 (-5.21%)
Updated
Dec 5, 6:59 PM EST
82 days until earnings call
Ad is loading...

Compare predictions JAGX vs QURE

Header iconJAGX vs QURE Comparison
Open Charts JAGX vs QUREBanner chart's image
Jaguar Health
Price$0.32
Change-$0.07 (-17.95%)
Volume$3.68M
CapitalizationN/A
uniQure
Price$6.73
Change-$0.37 (-5.21%)
Volume$582.53K
CapitalizationN/A
View a ticker or compare two or three
JAGX vs QURE Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
JAGX vs. QURE commentary
Dec 06, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a StrongSell and QURE is a StrongBuy.

COMPARISON
Comparison
Dec 06, 2023
Stock price -- (JAGX: $0.32 vs. QURE: $6.73)
Brand notoriety: JAGX and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 114% vs. QURE: 96%
Market capitalization -- JAGX: $17.75M vs. QURE: $335.64M
JAGX [@Biotechnology] is valued at $17.75M. QURE’s [@Biotechnology] market capitalization is $335.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 0 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • JAGX’s FA Score: 0 green, 5 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, QURE is a better buy in the long-term than JAGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 3 TA indicator(s) are bullish while QURE’s TA Score has 6 bullish TA indicator(s).

  • JAGX’s TA Score: 3 bullish, 5 bearish.
  • QURE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, QURE is a better buy in the short-term than JAGX.

Price Growth

JAGX (@Biotechnology) experienced а -7.06% price change this week, while QURE (@Biotechnology) price change was -3.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +12.28%. For the same industry, the average monthly price growth was +25.03%, and the average quarterly price growth was +26.76%.

Reported Earning Dates

JAGX is expected to report earnings on May 19, 2023.

QURE is expected to report earnings on Feb 26, 2024.

Industries' Descriptions

@Biotechnology (+12.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for JAGX with price predictions.
OPEN
A.I.dvisor published
a Summary for QURE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
QURE($336M) has a higher market cap than JAGX($17.7M). QURE YTD gains are higher at: -70.313 vs. JAGX (-95.029). JAGX has higher annual earnings (EBITDA): -29.66M vs. QURE (-190.47M). QURE has more cash in the bank: 659M vs. JAGX (3.23M). JAGX has less debt than QURE: JAGX (35.5M) vs QURE (138M). QURE has higher revenues than JAGX: QURE (112M) vs JAGX (10.7M).
JAGXQUREJAGX / QURE
Capitalization17.7M336M5%
EBITDA-29.66M-190.47M16%
Gain YTD-95.029-70.313135%
P/E RatioN/A2.68-
Revenue10.7M112M10%
Total Cash3.23M659M0%
Total Debt35.5M138M26%
FUNDAMENTALS RATINGS
JAGX vs QURE: Fundamental Ratings
JAGX
QURE
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
10087
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for JAGX (74) in the Pharmaceuticals Generic industry. This means that QURE’s stock grew somewhat faster than JAGX’s over the last 12 months.

QURE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that QURE’s stock grew similarly to JAGX’s over the last 12 months.

QURE's SMR Rating (97) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that QURE’s stock grew similarly to JAGX’s over the last 12 months.

QURE's Price Growth Rating (64) in the Biotechnology industry is in the same range as JAGX (65) in the Pharmaceuticals Generic industry. This means that QURE’s stock grew similarly to JAGX’s over the last 12 months.

QURE's P/E Growth Rating (87) in the Biotechnology industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that QURE’s stock grew similarly to JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXQURE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 6 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 9 days ago
73%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 1 day ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STRM0.310.02
+7.86%
Streamline Health Solutions
PDSB5.24-0.04
-0.76%
PDS Biotechnology Corp
FTV68.30-1.23
-1.77%
Fortive Corp
SGML28.09-1.79
-5.99%
Sigma Lithium Corp
ZIM7.29-0.77
-9.55%
ZIM Integrated Shipping Services Ltd

JAGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAGX has been loosely correlated with IBRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if JAGX jumps, then IBRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-16.92%
IBRX - JAGX
37%
Loosely correlated
-1.08%
HEPA - JAGX
29%
Poorly correlated
-2.42%
LGVN - JAGX
28%
Poorly correlated
+4.41%
VXRT - JAGX
28%
Poorly correlated
-2.90%
SRNEQ - JAGX
27%
Poorly correlated
-8.17%
More